Pharmacological Foundations of Parkinson’s Disease
From Mechanisms to Clinical Practice
- 1st Edition - September 1, 2026
- Latest edition
- Editor: Wael Mohamed
- Language: English
Pharmacotherapy of Parkinson's Disease: from Basics to Practice provides a comprehensive guide on the pharmacological treatment of Parkinson's Disease, offering students and clinic… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
Pharmacotherapy of Parkinson's Disease: from Basics to Practice provides a comprehensive guide on the pharmacological treatment of Parkinson's Disease, offering students and clinicians a combination of foundational knowledge and advanced clinical insights. The book bridges theoretical concepts with real-world clinical scenarios and equips readers with the tools necessary to effectively manage Parkinson's Disease in practice. Offering a detailed review of symptoms, treatment gaps, and emerging therapies, this book delves into the pathogenesis the disease, along with dopaminergic treatments and management of motor and non-motor symptoms.
Providing updates on emerging therapies, including innovative treatment approaches, this book serves as a valuable reference for continuous learning and staying current with evolving practices and research in Parkinson's Disease management.
Providing updates on emerging therapies, including innovative treatment approaches, this book serves as a valuable reference for continuous learning and staying current with evolving practices and research in Parkinson's Disease management.
Key features
Key features
- Reviews current pharmacological treatments for Parkinson's Disease, from foundational principles to advanced applications
- Outlines the latest treatment protocols, therapeutic strategies, and emerging trends in Parkinson’s Disease pharmacotherapy
- Provides detailed insights into how different drugs operate at the molecular and cellular levels, enhancing comprehension of PD pathophysiology and drug mechanisms
- Presents case studies, clinical trial outcomes, and real-world applications, detailing practical insights applicable to both research and clinical practice
Readership
Readership
Neurologist, Movement Disorder Specialists, Clinical Pharmacists, PAs, Medical Researchers, Medical Students and Residents, Pharmacologists
Table of contents
Table of contents
Section I: Introduction
1. Parkinson’s Disease Pathogenesis: From Molecular Insights to Novel Therapies
2. Cultural and Regional Considerations in Parkinson’s Pharmacotherapy
3. The Tango of Parkinson’s Treatment: The Dance of Balance and Harmony
4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson’s Disease
5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson’s Disease: A Systematic Review
Section II: L-DOPA and DOPAMINERGIC AGENTS
6. Dopaminergic Treatments for Parkinson’s Disease: Seeing the Unseen
7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones
8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents
9. Non-Dopaminergic Therapies
Section III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE
10. Management of Motor Symptoms
11. Non-Motor Symptoms and Their Pharmacological Management
12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease
13. Clinical Case Studies and Practical Applications
14. Epigenetic Modulators: Emerging Players in Parkinson’s Pharmacotherapy
Section IV: FUTURE THERAPEUTIC POSSIBILITIES
15. Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease
16. Future Directions in Parkinson's Disease Pharmacotherapy
17. Pioneering The Next Generation Of Therapies
18. Genetic Therapies for Parkinson’s Disease: The Dawn of Precision Medicine
19. The Gastrointestinal Microbiota and Parkinson’s Disease: What is known and what is still unknown.
20. Artificial Intelligence and Machine Learning in Parkinson’s Drug Development
21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson’s Disease
Section V: PHARMACOTHERAPY: HOPES AND HYPES
22. Neuroprotective Therapies in Parkinson's Disease
23. Polypharmacy and combination therapies in Parkinson’s Disease
24. Repurposing Existing Drugs for Parkinson’s Disease Management
25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice
26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy
27. Natural products in the management of Parkinson’s disease in animal models
Section VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY
28. Cognitive Enhancers in Parkinson’s Disease
29. Emerging Targets for Cognitive Enhancement
30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy
31. Personalized Medicine for Cognitive Impairments in PD
32. Ethical and Practical Challenges with Cognitive Enhancers
33. Unani Pharmacotherapy in the Management of Parkinson’s disease: A Therapeutic Approach
34. Music therapy and its synergy with pharmacotherapy in Parkinson’s Disease
35. Summary and Conclusion
1. Parkinson’s Disease Pathogenesis: From Molecular Insights to Novel Therapies
2. Cultural and Regional Considerations in Parkinson’s Pharmacotherapy
3. The Tango of Parkinson’s Treatment: The Dance of Balance and Harmony
4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson’s Disease
5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson’s Disease: A Systematic Review
Section II: L-DOPA and DOPAMINERGIC AGENTS
6. Dopaminergic Treatments for Parkinson’s Disease: Seeing the Unseen
7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones
8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents
9. Non-Dopaminergic Therapies
Section III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE
10. Management of Motor Symptoms
11. Non-Motor Symptoms and Their Pharmacological Management
12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease
13. Clinical Case Studies and Practical Applications
14. Epigenetic Modulators: Emerging Players in Parkinson’s Pharmacotherapy
Section IV: FUTURE THERAPEUTIC POSSIBILITIES
15. Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease
16. Future Directions in Parkinson's Disease Pharmacotherapy
17. Pioneering The Next Generation Of Therapies
18. Genetic Therapies for Parkinson’s Disease: The Dawn of Precision Medicine
19. The Gastrointestinal Microbiota and Parkinson’s Disease: What is known and what is still unknown.
20. Artificial Intelligence and Machine Learning in Parkinson’s Drug Development
21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson’s Disease
Section V: PHARMACOTHERAPY: HOPES AND HYPES
22. Neuroprotective Therapies in Parkinson's Disease
23. Polypharmacy and combination therapies in Parkinson’s Disease
24. Repurposing Existing Drugs for Parkinson’s Disease Management
25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice
26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy
27. Natural products in the management of Parkinson’s disease in animal models
Section VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY
28. Cognitive Enhancers in Parkinson’s Disease
29. Emerging Targets for Cognitive Enhancement
30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy
31. Personalized Medicine for Cognitive Impairments in PD
32. Ethical and Practical Challenges with Cognitive Enhancers
33. Unani Pharmacotherapy in the Management of Parkinson’s disease: A Therapeutic Approach
34. Music therapy and its synergy with pharmacotherapy in Parkinson’s Disease
35. Summary and Conclusion
Product details
Product details
- Edition: 1
- Latest edition
- Published: September 1, 2026
- Language: English
About the editor
About the editor
WM
Wael Mohamed
Dr. Wael Mohamed Yousef Mohamed is Professor of Basic Medical Science at the International Islamic University Malaysia, with over 20 years of experience in translational brain research and longevity science. He earned his MD and MSc in Clinical Pharmacology from Meoufia Medical School, Egypt, and his PhD in Neuroscience from The Pennsylvania State University. His research focuses on aging-related neurodegeneration, particularly Alzheimer’s and Parkinson’s diseases, aiming to understand the biological mechanisms of aging and develop therapies to extend healthspan. Dr. Mohamed investigates how aging influences neurodegenerative processes and seeks targeted interventions to promote healthy longevity. He is a member of leading neuroscience societies, including the Society for Neuroscience. His prior editorial work with Elsevier includes titles on neurodegenerative and movement disorders, reflecting his expertise in aging, neurodegeneration, and longevity.
Affiliations and expertise
Neuroscientist and Pharmacologist, Kulliyyah of Medicine, International Islamic University Malaysia; Founder and Chair, AfrAbia PD Genomic Consortium, Malaysia